Company: BIAF
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010787
Chunk: 38

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 38
---
308,415  
     342,098 
  
    Finance lease liability, net of current portion 
     335,899  
     444,448 
  
    Notes payable, net of current portion 
     48,156  
     20,180 

    Total liabilities 
     4,107,879  
     3,911,631 

    Commitments and contingencies (See Note 11) 
     -  
     - 

    Stockholders’ equity: 

    Preferred stock, no shares issued or outstanding at March 31, 2025, and December 31, 2024, respectively 
     —  
     — 
  
    Common stock, par value $0.007 per share; 100,000,000 shares authorized; 18,255,825 and 15,576,674 shares issued and outstanding as of March 31, 2025, and December 31, 2024, respectively 
     124,777  
     106,593 
  
    Additional paid-in capital 
     57,619,354  
     56,139,753 
  
    Accumulated deficit 
     (56,304,727) 
     (53,644,310)
  
    Total stockholders’ equity 
     1,439,404  
     2,602,036 

    Total liabilities, and stockholders’ equity 
    $5,547,283  
    $6,513,667 

The accompanying notes are an integral part of these
condensed consolidated financial statements.

5

bioAffinity Technologies, Inc.

Unaudited Consolidated Statements of Operations

    2025  
    2024 

    Three Months Ended  March 31, 

    2025  
    2024 

    Net Revenue 
    $1,853,597  
    $2,406,391 

    Operating expenses: 

    Direct costs and expenses 
     1,367,860  
     1,573,441 
  
    Research and development 
     367,386  
     393,639 
  
    Clinical development 
     138,353  
     48,960 
  
    Selling, general and administrative 
     2,452,549  
     2,185,944 
  
    Dep